StageZero Life Sciences Ltd. (OTCMKTS:GNWSF) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 62,500 shares, a drop of 18.7% from the March 15th total of 76,900 shares. Based on an average daily trading volume, of 75,300 shares, the short-interest ratio is currently 0.8 days.
StageZero Life Sciences stock opened at $0.58 on Wednesday. The stock has a market cap of $36.11 million, a price-to-earnings ratio of -2.24 and a beta of 3.02. The company’s 50-day moving average price is $0.88 and its two-hundred day moving average price is $0.72. StageZero Life Sciences has a 52 week low of $0.30 and a 52 week high of $1.27.
Separately, Clarus Securities cut shares of StageZero Life Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 6th.
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.